August 9, 2022
The US FDA has approved Myfembree (relugolix + estradiol + norethindrone acetate) for an additional endometriosis indication, Myovant Sciences, a subsidiary of Sumitomo Pharma, and US partner Pfizer said on August 5. The approval was granted for the management of...read more